GlassScriptPhysician profile
Naveen Singri
NPI 1215994744
$11,427.37
in general payments reported to CMS, 2019-2025
33 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,244 · 2020: $1,181 · 2021: $225 · 2022: $451 · 2023: $558 · 2024: $308 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282 · Education: $44.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,282.46 |
| Education | $44.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $6,038.41 | 2019-2020 | |
| Outset Medical INC | $2,685.13 | 2019 | |
| Glaxosmithkline, LLC. | $353.30 | 2021-2023 | Jesduvroq, Benlysta |
| Aurinia Pharma U.S., INC. | $332.02 | 2021-2023 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $246.45 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.99 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $168.86 | 2019-2025 | Velphoro |
| Amgen INC. | $116.27 | 2019-2025 | Tavneos, Krystexxa |
| Calliditas Therapeutics US INC. | $113.96 | 2024 | |
| Novo Nordisk INC | $109.94 | 2023-2025 | Ozempic |
| Otsuka America Pharmaceutical, INC. | $108.01 | 2019-2024 | Jynarque |
| Novartis Pharmaceuticals Corporation | $105.98 | 2019-2025 | |
| Vifor Pharma, INC. | $103.13 | 2019-2025 | Veltassa, Korsuva |
| Alexion Pharmaceuticals, INC. | $96.50 | 2019-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $91.09 | 2019-2024 | Farxiga |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $51.79 | 2023-2025 | Filspari |
| Amag Pharmaceuticals, INC. | $48.03 | 2019-2020 | |
| Daiichi Sankyo INC. | $47.72 | 2019-2021 | |
| Akebia Therapeutics INC | $47.59 | 2019-2020 | |
| Horizon Therapeutics Plc | $44.73 | 2019-2020 | |
| Ardelyx, INC. | $38.81 | 2023-2024 | Ibsrela |
| Baxter Healthcare | $38.39 | 2019 | |
| Mallinckrodt Hospital Products INC. | $36.09 | 2020-2023 | Terlivaz |
| Genzyme Corporation | $33.15 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $31.81 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $26.26 | 2019-2020 | |
| Shire North American Group INC | $21.34 | 2019 | |
| Mallinckrodt Enterprises LLC | $21.32 | 2019 | |
| Mannkind Corporation | $20.08 | 2025 | |
| Apellis Pharmaceuticals, INC. | $17.73 | 2025 | Empaveli |
| Ultragenyx Pharmaceutical INC. | $16.52 | 2020 | |
| Genentech USA, INC. | $15.97 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveen Singri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.